Acute airways disease: fenoterol and ipratropium improve FEV1 .
|
|
|
Clinical bottom line (level 1b-)
-
In patients with acute asthma or exacerbation of COPD, ipratropium, fenoterol and ipratropium plus fenoterol all increased the FEV
1
significantly by 45 minutes.
-
Ipratropium plus fenoterol may be more effective in asthmatics than ipratropium alone, but there was no clear difference between the other regimens.
|
|
Rebuck et al:
American Journal of Medicine
1987;
82:
59-64
|
Expires
June 2003
|
The study
Double-blinded concealed randomised
trial
without
intention-to-treat
Setting: four university hospitals, Canada
202 patients
(aged
?,
?%
male)
presented at emergency room for treatment of acute asthma or acute exacerbations of chronic obstructive pulmonary disease
Excluded if
- aged <18 years
- unable to perform forced expiratory test
- FEV
1
>70% of predicted
- complicating medical illnesses
- pregnant or nursing mothers
- received nebulised bronchodilator solution in previous six hours
- required treatment with drugs other than those specified in protocol
Note: - Patients were stratified by centre.
- Each centre had 50 enrolled patients.
- 150 (148 analysed) patients had asthma and 52 (51 analysed) had chronic obstructive pulmonary disease (COPD)
Control Group: (n = 68, 65 analysed):
ipratropium bromide
, 0.5 mg
Experimental Group: (n = 68, 68 analysed):
fenoterol hydrobromide
, 1.25 mg
Experimental Group: (n = 66, 66 analysed):
0.5 mg
ipratropium
plus 1.25 mg
fenoterol
Treatment with iv aminophylline or iv corticosteroids was given at the discretion of the attending physicians.
99% followed for
90
minutes
The evidence
ipratropium vs fenoterol in asthmatics at 45 minutes
| Outcome |
Control Group (SD) |
Experimental Group (SD) |
Mean Difference (95% CI) |
| FEV
1
(litres)
|
1.42
(0.78)
|
1.46
(0.80)
|
0.04
(-0.28 to 0.36)
|
ipratropium vs fenoterol in COPD at 45 minutes
| Outcome |
Control Group (SD) |
Experimental Group (SD) |
Mean Difference (95% CI) |
| FEV
1
(litres)
|
0.82
(0.34)
|
0.86
(0.37)
|
0.04
(-0.21 to 0.29)
|
fenoterol vs fenoterol plus ipratropium in asthmatics at 45 minutes
| Outcome |
Control Group (SD) |
Experimental Group (SD) |
Mean Difference (95% CI) |
| FEV
1
(litres)
|
1.46
(0.80)
|
1.75
(0.88)
|
0.29
(-0.049 to 0.63)
|
fenoterol vs fenoterol plus ipratropium in COPD at 45 minutes
| Outcome |
Control Group (SD) |
Experimental Group (SD) |
Mean Difference (95% CI) |
| FEV
1
(litres)
|
0.86
(0.37)
|
0.79
(0.41)
|
-0.07
(-0.33 to 0.19)
|
ipratropium vs fenoterol plus ipratropium in asthmatics at 45 minutes
| Outcome |
Control Group (SD) |
Experimental Group (SD) |
Mean Difference (95% CI) |
| FEV
1
|
1.42
(0.78)
|
1.75
(0.88)
|
0.33
(0.00 to 0.66)
|
ipratropium vs fenoterol plus ipratropium in COPD at 45 minutes
| Outcome |
Control Group (SD) |
Experimental Group (SD) |
Mean Difference (95% CI) |
| FEV
1
|
0.82
(0.34)
|
0.79
(0.41)
|
-0.03
(-0.31 to 0.25)
|
- All three regimens produced significant increases in FEV1 from baseline.
- There was no clear difference in FEV1 at 90 minutes.
Comments
- Theis is of historical interest as fenoterol is no longer available (as safety concerns have been raised).
- Cochrane reviews have shown a similar slight benefit to adding ipratropium to beta-agonist therapy.
Citation
-
Rebuck
AS,
Chapman
KR,
Abboud
R, et al:
Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room.
American Journal of Medicine
1987;
82:
59-64
Contributor: Clare Wotton and Musab Hayatli,
June 2000
Reviewer: Gerard Ryan
Clinical Question.
| Patient |
acute airways obstruction |
| Intervention or Exposure |
ipratropium bromide, fenoterol or both |
| Outcome |
forced expiratory volume in one second |
|
|